EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antithrombin: Deficiency, Diversity, and the Future of Diagnostics

Mirjam Kruijt, Christa M Cobbaert, L Renee Ruhaak

Mass Spectrometry Reviews · 2026-07 · 45 (4) · 745-768

DOI: 10.1002/mas.21929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mass Spectrometry Reviews, online erschienen am 15.03.2025. Verfasst von Mirjam Kruijt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Antithrombin III Deficiency, Mass Spectrometry, Antithrombins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable. Alternatively, P5 healthcare is proposed focusing on five key elements: prevention, personalization, prediction, participation, psychocognition, however, changes in current clinical care pathways are required, for which antithrombin deficiency is a prime example. Hereditary antithrombin deficiency (ATD) is a genetic disorder, for which screening is instigated after a thrombotic episode. Current diagnostic tests for ATD lack sensitivity and refinement to correctly classify patients, and generic treatments are prescribed. A molecular understanding of ATD through a molecular diagnostic test that analyzes all clinically relevant features of antithrombin is required. Here, clinically relevant molecular characteristics of antithrombin, the diversity of antithrombin (deficiency) in heath and disease, and the strengths and weaknesses of antithrombin tests are reviewed. A mass spectrometry test that molecularly characterizes a patients antithrombin proteoforms harbors the highest potential to improve the clinical pathway for ATD. Application of this MS‐based test in a future enhanced clinical pathway will improve patient management and outcome through molecular characterization of antithrombin and enables the promise of P5 healthcare for ATD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antithrombin III DeficiencyMass SpectrometryAntithrombinsHumansAntithrombin III

Stichwörter der Autor:innen

antithrombindiagnosticsmass spectrometrymedical test developmentproteoforms

Substanzen

AntithrombinsAntithrombin III

Autor:innen und Institutionen

  • Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Zitieren

APA

Kruijt, M., Cobbaert, C. M., & Ruhaak, L. R. (2026). Antithrombin: Deficiency, Diversity, and the Future of Diagnostics. Mass Spectrometry Reviews, 45(4), 745-768. https://doi.org/10.1002/mas.21929

Vancouver

Kruijt M, Cobbaert CM, Ruhaak LR. Antithrombin: Deficiency, Diversity, and the Future of Diagnostics. Mass Spectrometry Reviews. 2026;45(4):745-768. doi:10.1002/mas.21929

BibTeX
@article{Kruijt2026,
  author = {Kruijt, Mirjam and Cobbaert, Christa M and Ruhaak, L Renee},
  title = {Antithrombin: Deficiency, Diversity, and the Future of Diagnostics},
  journal = {Mass Spectrometry Reviews},
  year = {2026},
  volume = {45},
  number = {4},
  pages = {745--768},
  doi = {10.1002/mas.21929}
}
Kostenlos starten →